Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director
GOTHENBURG, Sweden, March 9, 2026 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) proposes re-election of all the current Board Directors and election of Christian Haglund as new Director at the Annual General Meeting on May 19, 2026.
The information in the press release is intended for investors.
The Nomination Committee in Isofol proposes that the Board of Directors, until the next Annual General Meeting, shall consist of six (6) ordinary members, without any alternate directors, as follows:
- Jan-Eric Österlund, Chairman, re-election
- Helena Taflin, re-election
- Alain Herrera, re-election
- Sten Nilsson, re-election
- Lars Lind, re-election
- Christian Haglund, new election
Christian Haglund was born in 1979 and holds a Master of Science in Business and Economics from Lund University. He is an experienced business executive and board member with deep expertise in finance, capital markets and investments. He has been a major shareholder in Isofol since 2023 and currently holds around 10.5% of Isofol’s issued shares.
Christian is co-founder of Intea Fastigheter AB (publ) (Nasdaq Stockholm: INTEA) and previously served as Deputy CEO and CFO of the company. He is also co-founder of Vacse AB (publ), where he had the role as CFO, and has also been Head of Financial Investments at Atlas Copco AB.
As an active investor, Christian is involved in several companies. He is a board member of, among others, Intea Fastigheter AB, VO2 Cap Holding AB (First North: VO2) and the fund management company Crescit Asset Management AB. He also serves as an investment advisor to the Epiroc Group Swedish Pension Fund.
The Nomination Committee for the 2026 Annual General Meeting consists of Johan Möller (chairman), Christian Haglund, Göran Gustafsson and Lars Lind.
The full proposals of the Nomination Committee will be published on Isofol’s website and will also be included in the notice convening the Annual General Meeting no later than April 21, 2026.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CET on March 9, 2026.
About Isofol
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.